The toll-like receptor 5 agonist entolimod mitigates lethal acute radiation syndrome in non-human primates

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Krivokrysenko, Vadim I ^a   Toshkov, Ilia A ^a,d   Gleiberman, Anatoli S ^a,d   Krasnov, Peter ^a,d   Shyshynova, Inna ^a   Bespalov, Ivan ^a,d   Maitra, Ratan K ^a   Narizhneva, Natalya V ^a   Singh, Vijay K ^b   Whitnall, Mark H ^b   Purmal, Andrei A ^a   Shakhov, Alexander N ^a   Gudkov, Andrei V ^a,c   Feinstein, Elena ^a  

^a CLEVELAND BIOLABS INC   (United States)

^b ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Buffalo BioLabs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTOLIMOD; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; PEPTIDE; RADIOPROTECTIVE AGENT; TOLL LIKE RECEPTOR 5;

ACUTE RADIATION SYNDROME; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; AUTOPSY; CLONOGENESIS; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DISEASE DURATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MECHANISM; EXPLORATORY RESEARCH; FEMALE; HEMATOPOIESIS; LD50; MALE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NEUTROPENIA; NONHUMAN; RADIATION EXPOSURE; RADIATION HAZARD; REGENERATION; RHESUS MONKEY; RISK REDUCTION; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; AGONISTS; ANIMAL; BONE MARROW; DRUG EFFECTS; INTESTINE MUCOSA; RADIATION RESPONSE;

ACUTE RADIATION SYNDROME; ANIMALS; BONE MARROW; FEMALE; HEMATOPOIESIS; INTESTINAL MUCOSA; MACACA MULATTA; MALE; PEPTIDES; RADIATION-PROTECTIVE AGENTS; TOLL-LIKE RECEPTOR 5;

EID: 84947579903     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135388     Document Type: Article

References (110)

1. Di Carlo AL, Maher C, Hick JL, Hanfling D, Dainiak N, Chao N, et al. Radiation injury after a nuclear detonation: medical consequences and the need for scarce resources allocation. Disaster Med Public Health Prep. 2011; 5 Suppl 1:S32-44. Epub 2011/03/22. doi: 10.1001/dmp.2011.17 PMID: 21402810.
2. Waselenko JK, MacVittie TJ, Blakely WF, Pesik N, Wiley AL, Dickerson WE, et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med. 2004; 140(12):1037-51. PMID: 15197022.
3. Dorr H, Meineke V. Acute radiation syndrome caused by accidental radiation exposure-therapeutic principles. BMC Med. 2011; 9:126. Epub 2011/11/26. doi: 10.1186/1741-7015-9-126 PMID: 22114866.
4. Singh VK, Newman VL, Romaine PL, Wise SY, Seed TM. Radiation countermeasure agents: an update (2011-2014). Expert Opin Ther Pat. 2014; 24(11):1229-55. Epub 2014/10/16. doi: 10.1517/13543776.2014.964684 PMID: 25315070.
5. Singh VK, Romaine PL, Newman VL. Biologics as countermeasures for acute radiation syndrome: where are we now? Expert Opin Biol Ther. 2014:1-7. Epub 2014/11/25. doi: 10.1517/14712598. 2015.986453 PMID: 25416452.
6. Singh VK, Newman VL, Seed TM. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review. Cytokine. 2015; 71(1):22-37. Epub 2014/09/13. doi: 10.1016/j.cyto.2014.08.003 PMID: 25215458.
7. Bensadoun RJ, Schubert MM, Lalla RV, Keefe D. Amifostine in the management of radiation-induced and chemo-induced mucositis. Support Care Cancer. 2006; 14(6):566-72. PMID: 16586122.
8. Singh PK, Wise SY, Ducey EJ, Brown DS, Singh VK. Radioprotective efficacy of tocopherol succinate is mediated through granulocyte-colony stimulating factor. Cytokine. 2011; 56(2):411-21. Epub 2011/09/02. doi: 10.1016/j.cyto.2011.08.016 PMID: 21880504.
9. Srinivasan V, Weiss JF. Radioprotection by vitamin E: injectable vitamin E administered alone or with WR-3689 enhances survival of irradiated mice. Int J Radiat Oncol Biol Phys. 1992; 23(4):841-5. Epub 1992/01/01. PMID: 1319980.
10. Whitnall MH, Wilhelmsen CL, McKinney L, Miner V, Seed TM, Jackson WE 3rd. Radioprotective efficacy and acute toxicity of 5-androstenediol after subcutaneous or oral administration in mice. Immunopharmacol Immunotoxicol. 2002; 24(4):595-626. PMID: 12510793.
11. Stickney DR, Dowding C, Authier S, Garsd A, Onizuka-Handa N, Reading C, et al. 5-androstenediol improves survival in clinically unsupported rhesus monkeys with radiation-induced myelosuppression. Int Immunopharmacol. 2007; 7(4):500-5. PMID: 17321473.
12. Gratwohl A, John L, Baldomero H, Roth J, Tichelli A, Nissen C, et al. FLT-3 ligand provides hematopoietic protection from total body irradiation in rabbits. Blood. 1998; 92(3):765-9. PMID: 9680342.
13. Zsebo KM, Smith KA, Hartley CA, Greenblatt M, Cooke K, Rich W, et al. Radioprotection of mice by recombinant rat stem cell factor. Proc Natl Acad Sci U S A. 1992; 89(20):9464-8. PMID: 1384054.
14. Dainiak N, Waselenko JK, Armitage JO, MacVittie TJ, Farese AM. The hematologist and radiation casualties. Hematology Am Soc Hematol Educ Program. 2003:473-96. PMID: 14633795.
15. Komarova EA, Gudkov AV. Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors. Biochem Pharmacol. 2001; 62(6):657-67. Epub 2001/09/15. PMID: 11556286.
16. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999; 285(5434):1733-7. PMID: 10481009.
17. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol. 2006; 2 (9):474-9. Epub 2006/07/25. doi: 10.1038/nchembio809 PMID: 16862141.
18. Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science. 2008; 320 (5873):226-30. Epub 2008/04/12. doi: 10.1126/science.1154986 PMID: 18403709.
19. Shakhov AN, Singh VK, Bone F, Cheney A, Kononov Y, Krasnov P, et al. Prevention and mitigation of acute radiation syndrome in mice by synthetic lipopeptide agonists of Toll-like receptor 2 (TLR2). PLoS One. 2012; 7(3):e33044. doi: 10.1371/journal.pone.0033044 PMID: 22479357
20. Singh VK, Ducey EJ, Fatanmi OO, Singh PK, Brown DS, Purmal A, et al. CBLB613: a TLR 2/6 agonist, natural lipopeptide of Mycoplasma arginini, as a novel radiation countermeasure. Radiat Res. 2012; 177(5):628-42. Epub 2011/12/20. doi: 10.1667/RR2657.1 PMID: 22175300.
21. Dev A, Iyer S, Razani B, Cheng G. NF-kappaB and innate immunity. Curr Top Microbiol Immunol. 2011; 349:115-43. Epub 2010/09/18. doi: 10.1007/82-2010-102 PMID: 20848362.
22. Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene. 2006; 25 (51):6758-80. PMID: 17072327.
23. Xu Y, Kiningham KK, Devalaraja MN, Yeh CC, Majima H, Kasarskis EJ, et al. An intronic NF-kappaB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-alpha and interleukin-1beta. DNA Cell Biol. 1999; 18(9):709-22. PMID: 10492402.
24. Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K, et al. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell. 2004; 119(4):529-42. PMID: 15537542.
25. Luo JL, Kamata H, Karin M. The anti-death machinery in IKK/NF-kappaB signaling. J Clin Immunol. 2005; 25(6):541-50. Epub 2005/12/29. doi: 10.1007/s10875-005-8217-6 PMID: 16380818.
26. Xiao M, Inal CE, Parekh VI, Chang CM, Whitnall MH. 5-Androstenediol promotes survival of gammairradiated human hematopoietic progenitors through induction of nuclear factor-kappaB activation and granulocyte colony-stimulating factor expression. Mol Pharmacol. 2007; 72(2):370-9. Epub 2007/05/03. doi: 10.1124/mol.107.035394 PMID: 17473057.
27. Basile LA, Ellefson D, Gluzman-Poltorak Z, Junes-Gill K, Mar V, Mendonca S, et al. Hema Max, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and nonhuman primates. PLoS One. 2012; 7(2):e30434. Epub 2012/03/03. doi: 10.1371/journal.pone. 0030434 PMID: 22383962.
28. Gluzman-Poltorak Z, Vainstein V, Basile LA. Recombinant interleukin-12, but not granulocyte-colony stimulating factor, improves survival in lethally irradiated nonhuman primates in the absence of supportive care: Evidence for the development of a frontline radiation medical countermeasure. Am J Hematol. 2014. Epub 2014/05/24. doi: 10.1002/ajh.23770 PMID: 24852354.
29. Gluzman-Poltorak Z, Mendonca SR, Vainstein V, Kha H, Basile LA. Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation. J Hematol Oncol. 2014; 7:31. Epub 2014/04/09. doi: 10.1186/1756-8722-7-31 PMID: 24708888.
30. US Department of Health and Human Services. Approval of biological products when human efficacy studies are not ethical or feasible. 21 CFR 601.
31. Dorr H, Lamkowski A, Graessle DH, Bennett A, Shapiro A, Farese AM, et al. Linking the human response to unplanned radiation and treatment to the nonhuman primate response to controlled radiation and treatment. Health Phys. 2014; 106(1):129-34. Epub 2013/11/28. PMID: 24276556.
32. Welters ID, Hafer G, Menzebach A, Muhling J, Neuhauser C, Browning P, et al. Ketamine inhibits transcription factors activator protein 1 and nuclear factor-kappaB, interleukin-8 production, as well as CD11b and CD16 expression: studies in human leukocytes and leukocytic cell lines. Anesth Analg. 2010; 110(3):934-41. Epub 2010/02/27. PMID: 20185670.
33. Miller LS, Morita Y, Rangan U, Kondo S, Clemens MG, Bulkley GB. Suppression of cytokine-induced neutrophil accumulation in rat mesenteric venules in vivo by general anesthesia. Int J Microcirc Clin Exp. 1996; 16(3):147-54. Epub 1996/05/01. PMID: 8856389.
34. Thomas J, Carver M, Haisch C, Thomas F, Welch J, Carchman R. Differential effects of intravenous anaesthetic agents on cell-mediated immunity in the Rhesus monkey. Clin Exp Immunol. 1982; 47 (2):457-66. Epub 1982/02/01. PMID: 6978785.
35. Sergio D. Animal Euthanasia. In: Chow PKH, Ng RTH, Ogden BE, editors. Using Animal Models in Biomedical Research: A Primer for the Investigator Hackensack, NJ: World Scientific; 2008.
36. Farese AM, Cohen MV, Katz BP, Smith CP, Gibbs A, Cohen DM, et al. Filgrastim improves survival in lethally irradiated nonhuman primates. Radiat Res. 2013; 179(1):89-100. Epub 2012/12/06. doi: 10.1667/RR3049.1 PMID: 23210705.
37. Farese AM, Brown CR, Smith CP, Gibbs AM, Katz BP, Johnson CS, et al. The Ability of Filgrastim to Mitigate Mortality Following LD50/60 Total-body Irradiation Is Administration Time-Dependent. Health Phys. 2014; 106(1):39-47. Epub 2013/11/28. PMID: 24276548.
38. Holdrinet RS, von Egmond J, Wessels JM, Haanen C. A method for quantification of peripheral blood admixture in bone marrow aspirates. Exp Hematol. 1980; 8(1):103-7. Epub 1980/01/01. PMID: 7409031.
39. Williams JP, Brown SL, Georges GE, Hauer-Jensen M, Hill RP, Huser AK, et al. Animal models for medical countermeasures to radiation exposure. Radiat Res. 2010; 173(4):557-78. Epub 2010/03/26. doi: 10.1667/RR1880.1 PMID: 20334528.
40. Maia GA, Reno Cde O, Medina JM, Silveira AB, Mignaco JA, Atella GC, et al. The effect of gamma radiation on the lipid profile of irradiated red blood cells. Ann Hematol. 2014; 93(5):753-60. Epub 2013/11/13. doi: 10.1007/s00277-013-1944-5 PMID: 24218190.
41. Rowe AW. Primates: models for red cell transfusion studies-cryopreservation and survival of transfused red cells in primates. J Med Primatol. 1994; 23(8):415-25. Epub 1994/10/01. PMID: 7602577.
42. Dominici M, Rasini V, Bussolari R, Chen X, Hofmann TJ, Spano C, et al. Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. Blood. 2009; 114(11):2333-43. Epub 2009/05/13. doi: 10.1182/blood-2008-10-183459 PMID: 19433859.
43. Yamazaki R, Kuwana M, Mori T, Okazaki Y, Kawakami Y, Ikeda Y, et al. Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. Bone Marrow Transplant. 2006; 38(5):377-84. Epub 2006/08/18. doi: 10.1038/sj.bmt.1705444 PMID: 16915226.
44. Potten CS, Merritt A, Hickman J, Hall P, Faranda A. Characterization of radiation-induced apoptosis in the small intestine and its biological implications. Int J Radiat Biol. 1994; 65(1):71-8. Epub 1994/01/01. PMID: 7905913.
45. Maj JG, Paris F, Haimovitz-Friedman A, Venkatraman E, Kolesnick R, Fuks Z. Microvascular function regulates intestinal crypt response to radiation. Cancer Res. 2003; 63(15):4338-41. PMID: 12907601.
46. Vigneulle RM, Rao S, Fasano A, MacVittie TJ. Structural and functional alterations of the gastrointestinal tract following radiation-induced injury in the rhesus monkey. Dig Dis Sci. 2002; 47(7):1480-91. Epub 2002/07/27. PMID: 12141804.
47. Wilson JW, Pritchard DM, Hickman JA, Potten CS. Radiation-induced p53 and p21WAF-1/CIP1 expression in the murine intestinal epithelium: apoptosis and cell cycle arrest. Am J Pathol. 1998; 153 (3):899-909. Epub 1998/09/15. PMID: 9736038.
48. Komarova EA, Kondratov RV, Wang K, Christov K, Golovkina TV, Goldblum JR, et al. Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene. 2004; 23(19):3265-71. PMID: 15064735.
49. Krivokrysenko VI, Shakhov AN, Singh VK, Bone F, Kononov Y, Shyshynova I, et al. Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure. J Pharmacol Exp Ther. 2012; 343(2):497-508. Epub 2012/07/28. doi: 10.1124/jpet.112.196071 PMID: 22837010.
50. van Eeden SF, Terashima T. Interleukin 8 (IL-8) and the release of leukocytes from the bone marrow. Leuk Lymphoma. 2000; 37(3-4):259-71. PMID: 10752978.
51. Hedrich CM, Bream JH. Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol Res. 2010; 47(1-3):185-206. Epub 2010/01/21. doi: 10.1007/s12026-009-8150-5 PMID: 20087682.
52. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011; 29:71-109. Epub 2010/12/21. doi: 10.1146/annurev-immunol-031210-101312 PMID: 21166540.
53. Benjamin G, McGeary MGH, McCutchen SR, Event. IoMUSCoMPfaTN. Assessing medical preparedness to respond to a terrorist nuclear event: workshop report. Washington, D.C.: National Academies Press; 2009. 168 p.
54. Burdelya LG, Brackett CM, Kojouharov B, Gitlin II, Leonova KI, Gleiberman AS, et al. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci U S A. 2013; 110(20):E1857-66. Epub 2013/05/01. doi: 10.1073/pnas.1222805110 PMID: 23630282.
55. Leigh ND, Bian G, Ding X, Liu H, Aygun-Sunar S, Burdelya LG, et al. A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity. PLoS One. 2014; 9(1): e85587. Epub 2014/01/24. doi: 10.1371/journal.pone.0085587 PMID: 24454895.
56. Burdelya LG, Gleiberman AS, Toshkov I, Aygun-Sunar S, Bapardekar M, Manderscheid-Kern P, et al. Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012; 83(1):228-34. Epub 2011/10/18. doi: 10.1016/j.ijrobp.2011.05.055 PMID: 22000579.
57. Kojouharov BM, Brackett CM, Veith JM, Johnson CP, Gitlin II, Toshkov IA, et al. Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice. Oncotarget. 2014; 5(3):802-14. Epub 2014/03/04. PMID: 24583651.
58. Anderson RF, Fisher LJ, Harris T. The 'pivotal antioxidant' hypothesis for the role of flavonoids in their reduction of HO∗ radical-induced damage on DNA. Redox Rep. 2001; 6(3):197-9. Epub 2001/08/29. PMID: 11523599.
59. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001; 410(6832):1099-103. PMID: 11323673.
60. Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, Barrett SL, et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol. 2003; 4(12):1247-53. PMID: 14625549.
61. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol. 2001; 167(4):1882-5. PMID: 11489966.
62. Feuillet V, Medjane S, Mondor I, Demaria O, Pagni PP, Galan JE, et al. Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria. Proc Natl Acad Sci U S A. 2006; 103(33):12487-92. PMID: 16891416.
63. Means TK, Hayashi F, Smith KD, Aderem A, Luster AD. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol. 2003; 170 (10):5165-75. Epub 2003/05/08. PMID: 12734364.
64. Vijay-Kumar M, Aitken JD, Sanders CJ, Frias A, Sloane VM, Xu J, et al. Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J Immunol. 2008; 180(12):8280-5. Epub 2008/06/05. PMID: 18523294.
65. Epperly MW, Sikora CA, De Filippi SJ, Gretton JA, Zhan Q, Kufe DW, et al. Manganese superoxide dismutase (SOD2) inhibits radiation-induced apoptosis by stabilization of the mitochondrial membrane. Radiat Res. 2002; 157(5):568-77. Epub 2002/04/23. PMID: 11966323.
66. Hendry JH, West CM. Apoptosis and mitotic cell death: their relative contributions to normal-tissue and tumour radiation response. Int J Radiat Biol. 1997; 71(6):709-19. Epub 1997/06/01. PMID: 9246185.
67. Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J. 2010; 430(2):199-205. Epub 2010/08/14. doi: 10.1042/BJ20100814 PMID: 20704571.
68. Sasi N, Hwang M, Jaboin J, Csiki I, Lu B. Regulated cell death pathways: new twists in modulation of BCL2 family function. Mol Cancer Ther. 2009; 8(6):1421-9. Epub 2009/06/11. doi: 10.1158/1535-7163.MCT-08-0895 PMID: 19509269.
69. Rolland SG, Conradt B. New role of the BCL2 family of proteins in the regulation of mitochondrial dynamics. Curr Opin Cell Biol. 2010; 22(6):852-8. Epub 2010/08/24. doi: 10.1016/j.ceb.2010.07.014 PMID: 20729050.
70. Wyllie AH. "Where, O death, is thy sting?" A brief review of apoptosis biology. Mol Neurobiol. 2010; 42 (1):4-9. Epub 2010/06/17. doi: 10.1007/s12035-010-8125-5 PMID: 20552413.
71. Yu Y, Nagai S, Wu H, Neish AS, Koyasu S, Gewirtz AT. TLR5-mediated phosphoinositide 3-kinase activation negatively regulates flagellin-induced proinflammatory gene expression. J Immunol. 2006; 176(10):6194-201. PMID: 16670329.
72. Parcellier A, Tintignac LA, Zhuravleva E, Hemmings BA. PKB and the mitochondria: AKTing on apoptosis. Cell Signal. 2008; 20(1):21-30. Epub 2007/08/25. doi: 10.1016/j.cellsig.2007.07.010 PMID: 17716864.
73. Jones RM, Sloane VM, Wu H, Luo L, Kumar A, Kumar MV, et al. Flagellin administration protects gut mucosal tissue from irradiation-induced apoptosis via MKP-7 activity. Gut. 2011; 60(5):648-57. Epub 2011/01/05. doi: 10.1136/gut.2010.223891 PMID: 21199832.
74. Francois S, El Benna J, Dang PM, Pedruzzi E, Gougerot-Pocidalo MA, Elbim C. Inhibition of neutrophil apoptosis by TLR agonists in whole blood: involvement of the phosphoinositide 3-kinase/Akt and NF-kappaB signaling pathways, leading to increased levels of Mcl-1, A1, and phosphorylated Bad. J Immunol. 2005; 174(6):3633-42. Epub 2005/03/08. PMID: 15749901.
75. Salamone GV, Petracca Y, Fuxman Bass JI, Rumbo M, Nahmod KA, Gabelloni ML, et al. Flagellin delays spontaneous human neutrophil apoptosis. Lab Invest. 2010; 90(7):1049-59. Epub 2010/04/07. doi: 10.1038/labinvest.2010.77 PMID: 20368700.
76. Carvalho FA, Aitken JD, Gewirtz AT, Vijay-Kumar M. TLR5 activation induces secretory interleukin-1 receptor antagonist (sIL-1Ra) and reduces inflammasome-associated tissue damage. Mucosal Immunol. 2011; 4(1):102-11. Epub 2010/09/17. doi: 10.1038/mi.2010.57 PMID: 20844479.
77. He XX, Bai H, Yang GR, Xue YJ, Su YN. [Expression of Toll-like receptors in human bone marrow mesenchemal stem cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009; 17(3):695-9. Epub 2009/06/25. PMID: 19549390.
78. van den Berk LC, Jansen BJ, Siebers-Vermeulen KG, Netea MG, Latuhihin T, Bergevoet S, et al. Tolllike receptor triggering in cord blood mesenchymal stem cells. J Cell Mol Med. 2009. Epub 2009/02/03.
79. Garcia-Castro J, Trigueros C, Madrenas J, Perez-Simon JA, Rodriguez R, Menendez P. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med. 2008; 12(6B):2552-65. Epub 2009/02/13. doi: 10.1111/j.1582-4934.2008.00516.x PMID: 19210755.
80. Neta R, Perlstein R, Vogel SN, Ledney GD, Abrams J. Role of interleukin 6 (IL-6) in protection from lethal irradiation and in endocrine responses to IL-1 and tumor necrosis factor. J Exp Med. 1992; 175 (3):689-94. Epub 1992/03/01. PMID: 1311016.
81. MacVittie TJ, Farese AM, Patchen ML, Myers LA. Therapeutic efficacy of recombinant interleukin-6 (IL-6) alone and combined with recombinant human IL-3 in a nonhuman primate model of high-dose, sublethal radiation-induced marrow aplasia. Blood. 1994; 84(8):2515-22. Epub 1994/10/15. PMID: 7919369.
82. Farrell CL, Bready JV, Rex KL, Chen JN, Di Palma CR, Whitcomb KL, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 1998; 58(5):933-9. PMID: 9500453.
83. MacVittie TJ, Farese AM, Smith WG, Baum CM, Burton E, McKearn JP. Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression. Blood. 2000; 95(3):837-45. Epub 2000/01/29. PMID: 10648394.
84. Bertho JM, Frick J, Prat M, Demarquay C, Dudoignon N, Trompier F, et al. Comparison of autologous cell therapy and granulocyte-colony stimulating factor (G-CSF) injection vs. G-CSF injection alone for the treatment of acute radiation syndrome in a non-human primate model. Int J Radiat Oncol Biol Phys. 2005; 63(3):911-20. Epub 2005/05/26. doi: 10.1016/j.ijrobp.2005.03.045 PMID: 15913916.
85. Dainiak N. Rationale and recommendations for treatment of radiation injury with cytokines. Health Phys. 2010; 98(6):838-42. Epub 2010/05/07. PMID: 20445391.
86. Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science. 1987; 236 (4806):1229-37. Epub 1987/06/05. PMID: 3296190.
87. Roberts AW. G-CSF: a key regulator of neutrophil production, but that's not all!. Growth Factors. 2005; 23(1):33-41. PMID: 16019425.
88. Zeidler C, Kanz L, Hurkuck F, Rittmann KL, Wildfang I, Kadoya T, et al. In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates. Blood. 1992; 80(11):2740-5. PMID: 1280477.
89. Na Nakorn T, Traver D, Weissman IL, Akashi K. Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J Clin Invest. 2002; 109(12):1579-85. Epub 2002/06/19. doi: 10.1172/JCI15272 PMID: 12070305.
90. Abtin A, Eckhart L, Glaser R, Gmeiner R, Mildner M, Tschachler E. The antimicrobial heterodimer S100A8/S100A9 (calprotectin) is upregulated by bacterial flagellin in human epidermal keratinocytes. J Invest Dermatol. 2010; 130(10):2423-30. Epub 2010/06/18. doi: 10.1038/jid.2010.158 PMID: 20555353.
91. Gao N, Kumar A, Jyot J, Yu FS. Flagellin-induced corneal antimicrobial peptide production and wound repair involve a novel NF-kappaB-independent and EGFR-dependent pathway. PLoS One. 2010; 5(2):e9351. Epub 2010/03/03. doi: 10.1371/journal.pone.0009351 PMID: 20195469.
92. Kumar A, Gao N, Standiford TJ, Gallo RL, Yu FS. Topical flagellin protects the injured corneas from Pseudomonas aeruginosa infection. Microbes Infect. 2010; 12(12-13):978-89. Epub 2010/07/06. doi: 10.1016/j.micinf.2010.06.007 PMID: 20601077.
93. Munoz N, Van Maele L, Marques JM, Rial A, Sirard JC, Chabalgoity JA. Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection. Infect Immun. 2010; 78 (10):4226-33. Epub 2010/07/21. doi: 10.1128/IAI.00224-10 PMID: 20643849.
94. Van Maele L, Carnoy C, Cayet D, Songhet P, Dumoutier L, Ferrero I, et al. TLR5 signaling stimulates the innate production of IL-17 and IL-22 by CD3(neg)CD127+ immune cells in spleen and mucosa. J Immunol. 2010; 185(2):1177-85. Epub 2010/06/23. doi: 10.4049/jimmunol.1000115 PMID: 20566828.
95. Yu FS, Cornicelli MD, Kovach MA, Newstead MW, Zeng X, Kumar A, et al. Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J Immunol. 2010; 185 (2):1142-9. Epub 2010/06/23. doi: 10.4049/jimmunol.1000509 PMID: 20566829.
96. Zgair AK. Flagellin administration protects respiratory tract from Burkholderia cepacia infection. J Microbiol Biotechnol. 2012; 22(7):907-16. Epub 2012/05/15. PMID: 22580309.
97. Silva SC, Baggio-Zappia GL, Brunialti MK, Assuncao MS, Azevedo LC, Machado FR, et al. Evaluation of Toll-like, chemokine, and integrin receptors on monocytes and neutrophils from peripheral blood of septic patients and their correlation with clinical outcomes. Braz J Med Biol Res. 2014; 47(5):384-93. Epub 2014/04/15. PMID: 24728213.
98. Janot L, Sirard JC, Secher T, Noulin N, Fick L, Akira S, et al. Radioresistant cells expressing TLR5 control the respiratory epithelium's innate immune responses to flagellin. Eur J Immunol. 2009; 39 (6):1587-96. Epub 2009/05/09. doi: 10.1002/eji.200838907 PMID: 19424969.
99. Koller B, Kappler M, Latzin P, Gaggar A, Schreiner M, Takyar S, et al. TLR expression on neutrophils at the pulmonary site of infection: TLR1/TLR2-mediated up-regulation of TLR5 expression in cystic fibrosis lung disease. J Immunol. 2008; 181(4):2753-63. Epub 2008/08/08. PMID: 18684966.
100. Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science. 2010; 328(5978):562-4. Epub 2010/05/01. doi: 10.1126/science.328.5978.562 PMID: 20430990.
101. Melican K, Boekel J, Mansson LE, Sandoval RM, Tanner GA, Kallskog O, et al. Bacterial infectionmediated mucosal signalling induces local renal ischaemia as a defence against sepsis. Cell Microbiol. 2008; 10(10):1987-98. Epub 2008/06/14. doi: 10.1111/j.1462-5822.2008.01182.x PMID: 18549455.
102. Hayon Y, Shai E, Varon D, Leker RR. The role of platelets and their microparticles in rehabilitation of ischemic brain tissue. CNS Neurol Disord Drug Targets. 2012; 11(7):921-5. Epub 2012/11/08. PMID: 23131157.
103. Pintucci G, Froum S, Pinnell J, Mignatti P, Rafii S, Green D. Trophic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). Thromb Haemost. 2002; 88(5):834-42. Epub 2002/11/13. PMID: 12428103.
104. Hasan UA, Trinchieri G, Vlach J. Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts. J Biol Chem. 2005; 280(21):20620-7. Epub 2005/03/25. doi: 10.1074/jbc. M500877200 PMID: 15788393.
105. Rabbani ZN, Batinic-Haberle I, Anscher MS, Huang J, Day BJ, Alexander E, et al. Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury. Int J Radiat Oncol Biol Phys. 2007; 67(2):573-80. Epub 2007/01/24. doi: 10.1016/j.ijrobp.2006.09.053 PMID: 17236973.
106. Lee JH, Park JW. A manganese porphyrin complex is a novel radiation protector. Free Radic Biol Med. 2004; 37(2):272-83. Epub 2004/06/19. doi: 10.1016/j.freeradbiomed.2004.04.029 PMID: 15203198.
107. Patchen ML, MacVittie TJ, Williams JL, Schwartz GN, Souza LM. Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery from radiation-induced hematopoietic depression. Blood. 1991; 77(3):472-80. Epub 1991/02/01. PMID: 1991164.
108. Patchen ML, Fischer R, MacVittie TJ. Effects of combined administration of interleukin-6 and granulocyte colony-stimulating factor on recovery from radiation-induced hemopoietic aplasia. Exp Hematol. 1993; 21(2):338-44. Epub 1993/02/01. PMID: 7678816.
109. D'Hondt V, Humblet Y, Guillaume T, Baatout S, Chatelain C, Berliere M, et al. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study. Blood. 1995; 85(9):2347-53. Epub 1995/05/01. PMID: 7537110.
110. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol. 1998; 70:83-243. Epub 1998/10/02. PMID: 9755338.